Sunday 18 October 2026
Export INO’s income statement to Excel — free account
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024. In the quarter to June 2026, revenue fell 83.2%, EPS grew 88.5% and free cash flow grew 13.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.99
0.05
−4.81%
Follow INO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (409.87%) | (296.36%) | (183.47%) | (328.45%) |
+8 more TTM periods Free account |
|
| (114.64%) | (123.95%) | (90.61%) | (122.52%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(3,573.43%) | (2,278.64%) | (425.11%) | 908.10% | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(0.99) | (1.21) | (1.90) | (1.71) | |
Free Cash Flow |
(80.58) | (83.35) | (88.92) | (89.02) | |
Capital Expenditures |
— | — | (0.29) | (0.10) | |
| Other line items | |||||
Cash ROIC |
(196.33%) | (190.51%) | (107.63%) | (206.63%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.20 | 0.98 | 1.04 | 0.82 | |
Depreciation/Fixed assets |
1.59 | 1.35 | 1.18 | 1.05 | |
Capex/Depreciation |
0.00 | 0.00 | (0.10) | (0.03) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.99) | (1.21) | (1.89) | (1.70) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates